Trial Profile

Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tretinoin (Primary) ; Gemcitabine; Paclitaxel
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Therapeutic Use
Acronyms STARPAC2

Most Recent Events

20 Jan 2025 Study design published in the BMC Cancer.
20 Dec 2024 Planned End Date changed from 29 May 2025 to 28 Feb 2029.
20 Dec 2024 Planned primary completion date changed from 30 Nov 2024 to 29 Jun 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com